<!-- PageNumber="2608" -->
<!-- PageHeader="HASUMI ET AL." -->


FIGURE 1 - Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits B16 melanoma tumor growth in vivo. (a) Subconfluent
cultures of PAE/PDGFRβ cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for 1 hr on ice (left panels).
Alternatively, PAE/PDGFRβ cells were incubated for 5 min at 37C with conditioned medium or increasing amounts of PDGF-BB (right pan-
els). PDGFRB phosphorylation was analyzed by PDGFRB and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed
fractions of cell lysates. (b) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle (◆), 3 μM STI571 (■), 1
μM PTK787 (▲) or 3 μM STI571 and 1 μM PTK787 (.). B16/mock (c) or B16/PDGF-BB (d) cells were inoculated subcutaneously to C57B16/J
mice. When the tumor volume reached 20 mm3, mice received either p.o. gavage of vehicle (◆), 100 mg/kg/day STI571 (), 25 mg/kg/day
PTK787 (▲) or 100 mg/kg/day STI571 and 25 mg/kg/day PTK787 (O). Treatment was given for 13 days for mice bearing B16/mock tumors (c)
and 8 days for mice bearing B16/PDGF-BB tumors (d). Tumor volumes, determined by palpation were followed over time. Results are presented
as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by post hoc analysis applying the Duncan adjust-
ment. Significance is shown for the last day of treatment: *, $p < 0.05$ compared to vehicle treatment; §, $p < 0.05$ compared to PTK787 treat-
ment; #, $p < 0.05$ compared to STI571 treatment. (e) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STI571
(25 mg/100 mg/kg/day; lanes 4 and 5), PTK787 (25 mg/kg/day, lanes 6 and 7), STI571 (100 mg/kg/day, lanes 8 and 9) or STI571 (200 mg/kg/
day, lanes 10 and 11). PDGFRB was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFRβ
and phospho-tyrosine (pTyr) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1).
The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFRβ band were compared to the first vehi-
cle-treated tumor to obtain the relative receptor phosphorylation.

![a PDGF-BB 50 ng/ml B16/mock clone B16/PDGF-BB clone B16/PDGF-BB clone PDGF-BB 0.1 ng/ml PDGF-BB 0.5 ng/ml PDGF-BB 5 ng/ml b 107 PBS PBS Cell number 106 $$M N \times 10 ^ { - 3 }$$ 200- IB: pTyr 105 200- IB: PDGFRB 104 0 2 Time (days) 4 6 8 C o vehicle (n=7) vehicle (n=8) Tumor volume (mm3) ST1571 (n=6) Tumor volume (mm3) STI571 (n=8) 500 PTK787 (n=5) 500 PTK787 (n=7) 400 PTK787/STI571 (n=7) 400 PTK787/STI571 (n=9) 300 § 300 200 § 200 S# 100 100 0 0 0 2 4 6 8 10 12 14 0 2 4 6 8 Time (days) Time (days) e $$M W \times 10 ^ { - 3 }$$ STI STI STI C Veh PTK PTK 100 200 250 IB:pTyr 150 250 IB: PDGFRB 150 - 1 1.3 0.6 0.2 1.4 0.9 0.1 0.6 0.1 0.1 Relative phosph. 1.15 0.40 1.15 0.35 0.10 Mean relative phosph.](figures/1.1)


# Results

In vitro characterization of a B16F10 melanoma clone
which produces PDGF-BB

A B16 melanoma cell line producing PDGF-BB (B16/PDGF-
BB) was previously established.20 This cell line was used to iso-
late a clone with robust PDGF-BB production that was selected
for further experiments. As shown in Figure 1a (left panels), con-
ditioned medium from the selected B16/PDGF-BB clone, but not
from a mock-transfected clone (B16/mock), induced strong
PDGFRB phosphorylation in porcine aortic endothelial cells

transfected with the PDGFRβ (PAE/PDGFRβ), indicating pro-
duction of a large amount of PDGF-BB. The amount of PDGF-
BB released into the conditioned medium was estimated by incu-
bating PAE/PDGFRβ cells with either conditioned medium or
increasing amounts of PDGF-BB. After 2 days, the B16/PDGF-
BB cells had released an amount of PDGF into the medium that
was in excess of 0.5 ng/ml PDGF-BB (Fig. 1a, right panels). It
should be noted that PDGF-BB sticks to both cells and plastic, so
this amount is likely to represent underestimation of the produc-
tion of PDGF-BB.
```